

A close-up photograph of three young African children in school uniforms. The child on the left is smiling broadly, showing their teeth. The child in the middle is looking slightly to the side with a neutral expression. The child on the right is looking directly at the camera with a neutral expression. They are all wearing blue and white vertically striped shirts.

reaching out

Antiretrovirals par excellence

 Mylan

Dear Concerned Citizen,

It was less than a decade ago that a compassionate business leader at Matrix Laboratories in India, N. Prasad, decided to take action in the fight against HIV/AIDS. His vision was to develop antiretroviral (ARV) drugs that people in the developing world could afford and make them widely available.

On the other side of the world, U.S.-based Mylan was entering its fifth decade as one of the country's most respected generic pharmaceuticals companies. Mylan's sense of social responsibility took expression in many ways, including a commitment to produce affordable versions of various orphan drugs.

In 2007, the two companies joined forces, motivated by a shared passion to serve others by addressing unmet needs. Today, Matrix is one of the world's largest suppliers of the active pharmaceutical ingredients used to make generic ARVs. It also maintains an impressive portfolio of finished dosage forms of ARVs, including pediatric therapies.

The hallmark of Mylan's ARV franchise to date is affordability. Mylan has continually reduced the cost of first-line therapies and significantly reduced that of second-line therapies. In 2009, for instance, the company made available the world's first second-line regimen costing less than \$500 per person per year, down from \$15,000.

But there's still so much more to do.

Of the more than 33 million people currently infected with HIV, approximately 10 million need treatment, but only about 4 million receive it. A major reason: Most of those needing treatment live in countries where access to proper medical care is limited.

Standing in the way is an extraordinarily complex supply chain, which all too often is further crippled by an inadequate treatment infrastructure. This system prevents countless people from getting the ARV drugs they need. Moreover, if the World Health Organization revises its guidelines to recommend that treatments begin earlier and with newer ARVs, the number of people needing help will increase by millions.

So we have pledged to do for access what we have done already for affordability – introduce innovations that make it a sustainable reality for everyone. The result will not only help get ARVs quickly to where they are needed, that same platform can be used to distribute other life-saving therapies, such as those for malaria and other infectious diseases.

We hope you find the attached brochure enlightening. It puts real faces on a cruel illness and explains why delivering good health around the corner and across the world is our company's calling.

Sincerely,

Robert J. Coury
Chairman and CEO
Mylan

Heather Bresch
President
Mylan

mylan's values

Service

We understand that “it’s not about us” – it’s about helping others – and we believe there’s no situation we can’t handle. We would do whatever it takes, work ‘round the clock, cross any river and spare no effort – all to meet someone’s need. We wrap our high quality products in high quality service.

Innovation

We are unconventional, visionary and bold. We “connect the dots” others overlook. We see possibilities and bring them to life. We love to challenge the status quo and introduce new and better ways to help people everywhere enjoy a higher quality of life. Having the courage to be a force for constructive change is in our DNA.

Teamwork

Together, we can run faster, reach higher and achieve more than any one of us can alone. We relish opportunities to collaborate because it’s invigorating, enlightening and powerful. When we join forces and plow through boundaries, we move mountains.

Integrity

Doing what’s right is sacred to us. We behave responsibly, even when nobody’s looking. We set high standards from which we never back down. This uncompromising ethical stance helps to keep our products pure, our workers safe and the environment clean.

Reliability

Dependable. Reliable. Call it what you will, we’ve made it a habit. We strive to be there through thick and thin, rain or shine, delivering on every promise, every time. That’s why people around the corner and across the world count on Mylan.

A woman with dark skin and short, dark hair is sitting on a bed. She is wearing a red zip-up sweater with a white fur collar. Her hands are clasped in her lap, and she has a ring on her left hand. She is looking down with a somber expression. The bed has a patterned blanket with green and white designs. The background is a plain, light-colored wall.

global epidemic

Nomphilo sits on her bed feeling extremely ill. She had begun her antiretroviral (ARV) treatment with a severely compromised immune system. She was able to get ARV drugs thanks to an HIV-treatment program that is making them easily available in the poor rural district of Lusikisiki in South Africa where she lives.

Since 1981, the human immunodeficiency virus (HIV) has caused an estimated 25 million deaths around the globe and devastated countless lives and communities.

Today, AIDS, the autoimmune deficiency syndrome caused by HIV, continues to be a major global health priority, as AIDS-related illnesses remain one of the world's leading causes of death. And while the latest data suggest that the percentage of adults living with HIV has stabilized, unacceptably high levels of new HIV infections and AIDS deaths persist: Every day, nearly 7,400 people become infected and nearly 5,500 lose their lives.

Of the more than 33 million people currently infected with HIV, approximately 10 million need treatment, but only about 4 million receive it – a heartbreaking statistic given the number of effective and affordable antiretroviral (ARV) treatments now available.

Addressing the disease is difficult because the majority of those infected with HIV do not know it. In addition, most of those affected live in developing countries, where access to proper medical care is limited.

Standing in the way is an extraordinarily complex supply chain, which all too often is further crippled by an inadequate treatment infrastructure. This system prevents countless people from getting the ARV drugs they need.

Consistent with its value of Service, Mylan has pledged to address these challenges. The company envisions a day – in the near future – when everyone needing ARV products receives them, and it is on a mission now to eliminate all remaining barriers to access.

Two of the youngsters in a special hospital for HIV-infected children in St. Petersburg, Russia. Approximately 940,000 people in Russia are infected with HIV.

AFFECTING

MILLIONS





bringing hope

Through ongoing innovation, Mylan is bringing hope to those living with HIV/AIDS.

Already the company has made tremendous strides in producing ever-more-affordable ARVs. It has continually reduced the cost of first-line therapies and significantly reduced that of second-line therapies, which people use if and when they develop resistance to initially prescribed treatments. In 2009, for instance, Mylan made available the world's first second-line regimen costing less than \$500 per person per year, down from \$15,000.

Mylan also is introducing in 2010 the regimen mentioned above as a single blister pack containing a once-daily dosage of medication. Compared to existing alternate regimens, which involve five or more pills taken twice a day, Mylan's offering, called a "second-line-in-box," contains three tablets. The reduced "pill burden" and once-a-day dosage increases the likelihood people will adhere to their treatment.

In addition, the company's scientists, who are adept at developing complex formulations, gained approval in 2009 for a heat-stable ARV tablet, Lopinavir/Ritonavir – the only one of its kind. The product can be distributed and used in warm climates where refrigeration infrastructure is not widely available.

Thanks to these innovations alone, the company's ARV products are helping nearly one-third of all people receiving treatment today for HIV/AIDS in the developing world.

To continue that tradition of bringing hope, Mylan now is turning its attention to making sure that anyone needing ARV therapies has sustainable access to them. Among the ideas Mylan advocates: Introduce innovations that dramatically streamline the ARV supply chain.

MYLAN MEANS INNOVATION

◀ The Blue House is a dispensary that treats people living with HIV/AIDS in the Mathare district in Kenya – one of the largest and most poverty-stricken shanty towns in Africa. People wait for a consultation or a prescription.

FOUNDATION

sex | Mylan



www.clintonfoundation.org

clintonfoundation

CLINTON FOUNDATION

clintonfoundation



WWW.CLINTONFOUNDATION.ORG



powerful partnerships

Mylan's progress in combating HIV/AIDS also reflects its powerful partnerships with a wide variety of external organizations that share its humanitarian goals.

Many of these organizations, such as the Clinton HIV/AIDS Initiative, or CHAI, focus in part on securing affordable supplies of ARVs – and have found in Mylan a tremendous ally. The company also is an active member of the Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria (GBC) – the pre-eminent organization leading the business community's fight against the disease. In 2008, Mylan joined many of the GBC's other member companies in pledging publicly to fight HIV/AIDS-related discrimination in the workplace.

As a corporation whose employees enjoy a proven track record for working together to efficiently manage its own sizable portfolio of resources globally, Mylan believes it can help dramatically streamline the world's ARV supply chain.

That means finding ways to leverage better the unique and valuable contributions of the chain's numerous participants, which include an intricate patchwork of governments, funding agencies, health authorities, distributors, commercial interests, medical clinics, drug manufacturers – and consumers. So Mylan is intensifying its efforts to examine the chain through their eyes. Then, it will collaborate closely with them and lend its considerable organizational talents to finding ways to achieve shared goals.

The benefits of a streamlined chain would be substantial. Not only would ARVs get to where they're needed quickly, that same platform could deliver therapies for malaria and other infectious diseases.

Mylan's commitment to this outcome demonstrates that its aim is to go far beyond merely producing generic pharmaceuticals, and instead to continue addressing unmet needs.

MYLAN MEANS TEAMWORK

◀ From left: Robert J. Coury, chairman and CEO of Mylan; N. Prasad, vice chairman of Matrix; and Bill Clinton, former U.S. president.

EDUCATION | AW


HIV-positive counselor, Ricardo, with Jorge (right) and his grandmother, Rosa, in Ecuador. Ricardo visits Jorge regularly at his home to advise him on how to live a healthy life with HIV. About 1.7 million people are estimated to be living with AIDS in Latin America; about 40,000 of them live in Ecuador.



AWARENESS

Education

Mylan believes in the healing power of knowledge. It's determined to help expand access to ARV therapies by ensuring that all participants in the supply chain know the truth: That generic drugs are just as safe and effective as their far-more-expensive branded counterparts. Further, unlike some companies that produce two different versions of a drug – one for regulated markets and one for unregulated markets – Mylan makes only one high quality version of all its products.



about mylan

MYLAN MEANS INTEGRITY

Mylan is one of the world's leading generic and specialty pharmaceutical companies, serving customers in more than 140 countries and territories. The company was founded in 1961 and is headquartered in the U.S.

Mylan has one of the industry's broadest and highest quality portfolios, whose more than 900 individual products cover a vast array of therapeutic categories, dosage forms and delivery systems. Mylan also operates Matrix, one of the world's largest manufacturers of active pharmaceutical ingredients (API), and runs Dey Pharma, a business focused on respiratory, allergy and psychiatric therapies.

The company's reputation for integrity has helped it achieve and sustain strong positions in many established generics markets and is helping it build share in several emerging pharmaceutical markets. Its commercial activities are supported by a fully integrated global technical operations platform. Mylan uses the platform to manage the production process from end to end, so as to offer drugs people can trust.

Mylan also has a long and unwavering dedication to supporting philanthropic causes, from the orphan drugs it manufactures for very small populations, to its ARV franchise, which helps a great many.

Delivering good health around the corner and across the world is the powerful aspiration motivating the company's approximately 15,500 employees, all of whom also are guided by Mylan's culture and values.

The company's goal is to become the world's most efficient generics and specialty pharmaceutical company, allowing it to provide affordable medications to more people in more places than ever before. Because at Mylan, anything less isn't good enough.



▲ Mylan President Heather Bresch.

▶ Kamkhanlian, HIV-positive, lies on his bed near his wife Sianching and daughter Doulian at a care center for people living with HIV/AIDS in Churachandpur, Manipur, India. Manipur has one of the highest rates of HIV infection in the country. Other hard-hit regions include Andhra Pradesh, Karnataka and Maharashtra.



about **matrix**

MYLAN MEANS RELIABILITY

Matrix Laboratories, a Mylan subsidiary based in India, is one of the world's largest producers of API.

Since 2003, Matrix has been making available a reliable supply of high quality, affordable ARV API to other generic drug manufacturers and is currently one of the world's largest producers of them. In 2007, Matrix began offering finished dosage forms and launched a line of pediatric ARVs. Today, Matrix is widely respected for the quality and dependability of its ARV franchise.

Its genesis is a tribute to the character of N. Prasad, who purchased an interest in Matrix in 2000 and happened to share Mylan's passion for addressing unmet needs. Moved by a chance encounter with an African government advisor tasked with securing more burial sites to accommodate the bodies of those dying from HIV/AIDS, Prasad rallied Matrix's team to produce a generic ARV product that people in the developing world could afford. The advisor had indicated that the cost of ARV medications generally placed them out of the reach of people who needed them.

Matrix currently offers an extensive ARV product portfolio, components of which have no brand counterpart. The portfolio is a testament to the ingenuity of Matrix's scientists, whose inventory of drug master files now exceeds 200.

Further, because Matrix has scale and is vertically integrated with Mylan, it's well positioned to achieve ongoing improvements in efficiency, a key success factor in the ARV business.



▲ Rajiv Malik, chief operating officer of Mylan, and S. Srinivasan, managing director and CEO of Matrix.

▶ Flor, HIV-positive, is a married housewife and grandmother in Mexico City, Mexico. A former union organizer, she has worked as an AIDS activist for several years. "I feel happy that I have finally removed the stigma I had earlier imposed on myself," she says.





ACCESS FOR ALL

In the Enkamanzi community in rural Swaziland, Maria takes care of eight of her AIDS-orphaned grandchildren and great-grandchildren. Six of her seven children have died from AIDS.



a few of our **strong** achievements

milestones

- ▶ First generics company to receive tentative approval from the Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for Tenofovir Disoproxil Fumarate Tablets, 300 mg.
- ▶ Received first pre-qualification approval from the World Health Organization and the first tentative approval from the FDA under PEPFAR for heat-resistant Lopinavir 200 mg + Ritonavir 50 mg Tablets.
- ▶ Received the first tentative approval from the FDA under PEPFAR for Emtricitabine 200 mg + Tenofovir Disoproxil Fumarate 300 mg Tablets.
- ▶ First generics company to receive tentative approval from the FDA for the fixed-dose combination of Tenofovir Disoproxil Fumarate 300 mg + Lamivudine 300 mg, a new drug approval.
- ▶ First generics company to receive tentative approval from the FDA under PEPFAR for the once-daily, fixed-dose combination of Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg + Efavirenz 600 mg Tablets.
- ▶ Selected by CHAI, under its UNITAID-funded projects, as the primary supplier of five ARV drugs used in second-line HIV/AIDS treatment regimens and as the primary supplier of seven ARVs used in pediatric treatment.
- ▶ First company to make available a second-line regimen costing less than \$500 per person per year.
- ▶ First generics company to receive tentative approval from the FDA under PEPFAR for the fixed-dose combination of Efavirenz + Lamivudine + Tenofovir Disoproxil Fumarate Tablets, 600 mg + 300 mg + 300 mg, a new drug approval.

accreditations

The following stringent regulatory authorities have approved Matrix's finished-dosage-form manufacturing facility:

- ▶ Food and Drug Administration (U.S.),
- ▶ World Health Organization (Switzerland),
- ▶ Medicines and Healthcare Products Regulatory Agency (U.K.),
- ▶ Medicines Control Council (South Africa),
- ▶ Therapeutic Goods Administration (Australia) and
- ▶ many other regulatory authorities in Africa and Asia.

An Indonesian child looks through a curtain as her mother gives a blood sample for HIV testing in a slum in Jakarta. The HIV epidemic in Indonesia is among the fastest growing in Asia, and has spread to more than 30 provinces there.





Mylan

1500 Corporate Drive
Canonsburg, Pa. 15317
UNITED STATES OF AMERICA

Tel: 724.514.1800

E-mail: gpa@mylan.com

www.mylan.com

Matrix

1-1-151/1, IV Floor
Sairam Towers
Alexander Road
Secunderabad - 500 003
INDIA

Tel: 91.40.2770 0363, 6632 7722

E-mail: matrix@matrixlabsindia.com

www.matrixlabsindia.com

► Children orphaned by the AIDS epidemic attend school in Rabour Village, Kenya.